Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Ab170530-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $119.90 | |
Ab170530-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $567.90 | |
Ab170530-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $1,017.90 | |
Ab170530-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,797.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Product Name | Etrolizumab (anti-α4β7), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to Integrin α4β7, >95%, high purity, Human IgG1 |
---|---|
Synonyms | Antigen CD49D antibody; CD49d antibody; IA4 antibody; Integrin alpha 4 subunit antibody; Integrin alpha IV antibody; Integrin beta 7 antibody; Integrin beta 7 subunit antibody; ITGA4 antibody; ITGB7 antibody; LPAM1 antibody; 269C wild type; CD49 antigen-l |
Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
Specificity | Integrin α4β7 |
Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
Conjugation | Unconjugated |
Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
Action Type | ANTAGONIST |
Mechanism of action | Inhibitor of integrin α4β7;Antibody of integrin; alpha 7 subunit;Antibody of integrin αEβ7 |
Product Description | Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD). Purity |
Antibody Type | Primary antibody |
---|---|
Clonality | Recombinant |
Isotype | Human IgG1 |
Light Chain Type | kappa |
SDS-PAGE | 27.0 kDa (Light Chain) & 51.3 kDa (Heavy Chain), under reducing conditions; 177.9 kDa, under non-reducing conditions. |
Purification Method | Protein A purified |
Purity | >95% |
Source | CHO supernatant |
Form | Liquid |
Concentration | Lot by Lot |
Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
Shipped In | Ice chest + Ice pads |
Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS | 1044758-60-2 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IMGT/mAb-DB | 362 |
---|---|
Wikipedia | Etrolizumab |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
ZJ23F1001296 | Certificate of Analysis | Oct 13, 2023 | Ab170530 |
ZJ23F1001297 | Certificate of Analysis | Oct 13, 2023 | Ab170530 |
1. Schön MP, Arya A, Murphy EA, Adams CM, Strauch UG, Agace WW, Marsal J, Donohue JP, Her H, Beier DR et al.. (1999) Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice.. J Immunol, 162 (11): (6641-9). [PMID:10352281] |
2. Hu MC, Crowe DT, Weissman IL, Holzmann B. (1992) Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer's patch-specific lymphocyte homing.. Proc Natl Acad Sci USA, 89 (17): (8254-8). [PMID:1518854] |
3. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S et al.. (2005) Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.. N Engl J Med, 352 (24): (2499-507). [PMID:15958805] |
4. Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, Strauch U, Burgess G, Spanton J, Martin SW et al.. (2011) The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study.. Gut, 60 (8): (1068-75). [PMID:21317177] |
5. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S et al.. (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis.. N Engl J Med, 369 (8): (699-710). [PMID:23964932] |
6. Holzmann B, McIntyre BW, Weissman IL. (1989) Identification of a murine Peyer's patch--specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha.. Cell, 56 (1): (37-46). [PMID:2463092] |
7. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A et al.. (2014) Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.. Lancet, 384 (9940): (309-18). [PMID:24814090] |
8. Karecla PI, Bowden SJ, Green SJ, Kilshaw PJ. (1995) Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7).. Eur J Immunol, 25 (3): (852-6). [PMID:7705417] |
9. Cepek KL, Parker CM, Madara JL, Brenner MB. (1993) Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells.. J Immunol, 150 (8 Pt 1): (3459-70). [PMID:8468482] |